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Abstract 
Chronic respiratory diseases are driven by inflammation, but some clinical conditions (severe 
asthma, COPD) are refractory to conventional anti-inflammatory therapies. Thus, novel anti-
inflammatory strategies are necessary. The mRNA destabilizing protein, tristetraprolin (TTP), is 
an anti-inflammatory molecule that functions to induce mRNA decay of cytokines that drive 
pathogenesis of respiratory disorders. TTP is regulated by phosphorylation and protein 
phosphatase 2A (PP2A) is responsible for dephosphorylating (and hence activating) TTP, 
amongst other targets. PP2A is activated by small molecules, FTY720 and AAL(S), and in this 
study we examine whether these compounds repress cytokine production in a cellular model of 
airway inflammation using A549 lung epithelial cells stimulated with tumor necrosis factor  
(TNF) in vitro. PP2A activators significantly increase TNF-induced PP2A activity and inhibit 
mRNA expression and protein secretion of interleukin 8 (IL-8) and IL-6; two key pro-
inflammatory cytokines implicated in respiratory disease and TTP targets. The effect of PP2A 
activators is not via an increase in TNF-induced TTP mRNA expression; instead we 
demonstrate a link between PP2A activation and TTP anti-inflammatory function by showing 
that specific knockdown of TTP with siRNA reversed the repression of TNF-induced IL-8 and 
IL-6 mRNA expression and protein secretion by FTY720. Therefore we propose that PP2A 
activators affect the dynamic equilibrium regulating TTP; shifting the equilibrium from 
phosphorylated (inactive) towards unphosphorylated (active) but unstable TTP. PP2A activators 
boost the anti-inflammatory function of TTP and have implications for future 
pharmacotherapeutic strategies to combat inflammation in respiratory disease. 
 
Keywords:  protein phosphatase 2A, tristetraprolin, TNF, inflammation, asthma 
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1. Introduction 
The prevalence of chronic respiratory disease is on the increase. Pathogenesis and disease 
progression are driven by inflammation, but in many clinical situations (severe asthma, 
infectious exacerbation, COPD), we do not have effective anti-inflammatory treatments [1-3]. 
Thus, alternative anti-inflammatory strategies are urgently needed. This is the potential of 
tristetraprolin (TTP). 
TTP is an mRNA destabilizing molecule that acts at the post-transcriptional level to inhibit the 
expression of many pro-inflammatory cytokines responsible for respiratory disease pathogenesis 
(reviewed in [4]). TTP is regulated by phosphorylation at a number of levels; gene expression, 
mRNA and protein stability is p38 MAPK-dependent [5, 6] and its anti-inflammatory action is 
controlled by the phosphorylation status of TTP protein at S52 and S178 [5-7]. There is a 
dynamic equilibrium between unphosphorylated and phosphorylated TTP. In the 
unphosphorylated state, TTP is active and can induce mRNA decay however; this form of TTP is 
also subject to degradation by the ubiquitin-proteasome system [6, 8]. When TTP is 
phosphorylated, the protein is stabilized [8-10], but this phosphorylated form of TTP is unable to 
cause mRNA decay, and therefore is inactive [7].  
When active, TTP has a substantial repressive impact on airway inflammation [6]. However, 
under respiratory disease conditions, although TTP is present, it is likely held in a dormant, 
inactive form due to the high levels of p38 MAPK phosphorylation [11]. Therefore developing a 
strategy to activate TTP under inflammatory conditions could be therapeutically useful. This 
dynamic equilibrium provides us with important points of regulatory control that we propose to 
exploit to enhance TTP function. However, blocking p38 MAPK with inhibitors in an attempt to 
promote greater amounts of unphosphorylated (active) TTP  doesn’t work because TTP is a p38 
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MAPK-responsive gene and this will result in less TTP mRNA expression [5, 12]. A better 
approach is to allow TTP to be expressed and then activate its mRNA destabilizing function. 
This is the promise of protein phosphatase 2A (PP2A), a serine/threonine phosphatase 
responsible for dephosphorylation of TTP at S52 and S178 [13]; amongst other molecules [14-
16]. PP2A is a ubiquitously expressed enzyme and in a recent publication [17] we demonstrated 
the important regulatory role exerted by PP2A under basal (unstimulated conditions) in the A549 
lung epithelial cell line. When PP2A basal enzymatic activity was removed, i.e. with the PP2A 
inhibitor okadaic acid or via specific knockdown of PP2A-C with siRNA, TTP was hyper-
phosphorylated and rendered non-functional [17]. Hence, proinflammatory cytokine production 
ensued. Therefore it follows that if TTP is switched off when PP2A activity is reduced, the 
corollary of these results is that TTP will be switched on by PP2A activators. This was the case 
under unstimulated conditions [17], but whether PP2A activators can switch TTP on and repress 
cytokine production under inflammatory conditions mimicked in vitro was currently unknown.  
We address this herein by utilizing a cellular model of airway inflammation using A549 lung 
epithelial cells [17-19] stimulated with tumor necrosis factor  (TNF) to mimic pro-
inflammatory conditions in vitro [17, 18]. We measure the impact on two key TTP targets 
implicated in respiratory disease, interleukin 8 (IL-8) and 6 (IL-6), as a functional outcome. We 
examine the ability of the sphingosine analog, FTY720, and the chiral analog of FTY720 devoid 
of sphingosine 1-phosphate (S1P) agonism, AAL(S) [17, 20-22] to activate PP2A and repress 
TNF-induced cytokine production in a TTP- dependent manner. Thus, in this study we address 
the hypothesis that PP2A activators can switch TTP on and repress cytokine production in an in 
vitro model of airway inflammation, and show for the first time that the PP2A activators FTY720 
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and AAL(S) repress TNF-induced IL-8 and IL-6 mRNA expression and protein secretion in a 
TTP-dependent manner.  
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2. Materials and Methods 
2.1 Chemicals 
FTY720 was purchased from the Cayman Chemical Company (Ann Arbor, MI) and AAL(S) (2-
amino-4-(4-heptyloxyphenyl)-2-methylbutanol) was synthesized [17, 20-22]. TNF is from 
R&D Systems (Minneapolis, MN). Unless otherwise specified, all chemicals used in this study 
were purchased from Sigma-Aldrich (St. Louis, MO). 
 
2.2 Cell culture 
The human alveolar epithelial cell line (A549) was cultured in Ham's F-12K (Kaighn's) medium 
(Invitrogen, Carlsbad, CA) supplemented with penicillin (100 U/ml), streptomycin (100 μg/ml), 
and fetal calf serum (10%) [17, 18]. All experiments were performed after an overnight serum-
starvation period (14-16 h) in Ham's F-12K supplemented with sterile BSA (0.1%) and 
stimulated with 4 ng/ml TNF in accordance with conditions originally reported by Cornell et al. 
[18].  A minimum of three experimental replicates performed on separate days were used for 
each experiment. 
 
2.3 PP2A activity assay 
PP2A activity was determined using the PP2A immunoprecipitation phosphatase assay kit 
(Merck Millipore, Darmstadt, Germany) according to the manufacturer's instructions. 
 
2.4 Real-time RT-PCR 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen Australia, Doncaster, VIC, 
Australia) and reverse transcription performed by using the RevertAid First strand cDNA 
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Synthesis kit (Fermentas Life Sciences, Hanover, MD) according to the manufacturer’s protocol. 
IL-8, IL-6 and TTP mRNA levels were measured using real-time RT-PCR on an ABI Prism 
7500 (Applied Biosystems, Foster City, CA) with IL-8 (Hs00174103_m1), IL-6 
(Hs00174131_m1) and TTP (Zfp36, Hs00185658_m1) TaqMan gene expression assays and the 
eukaryotic 18S rRNA endogenous control probe (Applied Biosystems) subjected to the 
following cycle parameters: 50°C for 2 min, 1 cycle; 95°C for 10 min, 1 cycle; 95°C for 15 s, 
60°C for 1 min, 40 cycles and mRNA expression (fold increase) quantified by delta delta Ct 
calculations. 
 
2.5 ELISA 
IL-8 and IL-6 ELISAs were performed according to the manufacturer’s instructions (BD 
Biosciences Pharmingen, San Diego, CA).    
 
2.6 Western blotting  
TTP was measured by Western blotting using rabbit antisera against TTP (Sak21) [5]. Detection 
of α-tubulin was used as the loading control (mouse monoclonal IgG1, DM1A: Santa Cruz 
Biotechnology, Santa Cruz, CA). p38 MAPK was detected using rabbit monoclonal or 
polyclonal antibodies against phosphorylated (Thr
180
/Tyr
182
) and total p38 MAPK (Cell 
Signaling Technology, Danvers, MA).  Primary antibodies were detected with goat anti-rabbit 
and anti-mouse HRP-conjugated secondary antibodies (Cell Signaling Technology, Danvers, 
MA) and visualized by enhanced chemiluminescence (PerkinElmer, Wellesley, MA).  
 
2.7 siRNA 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 8 
A549 cells (5 × 10
5
 cells/well) were transfected with siRNA against TTP, or scrambled control, 
by reverse transfection with RNAiMAX according to the manufacturer’s protocols (Invitrogen, 
NY, USA). Untransfected controls were also performed. Specifically, for each well of 6-well 
plates, 800 ng of ON-Target plus Control Non-targeting siRNA (scrambled control) or ON-target 
plus SMART pool Human TTP siRNA (aka Zfp36: both from Dharmacon, Thermo-Fisher 
Scientific, Waltham, MA) was diluted in 500 μL of Opti-MEM Reduced Serum Media 
(Invitrogen). This was followed by the addition of 5 μL of RNAiMAX reagent (Invitrogen) into 
each well and incubation at room temperature for 20 min. After transfection, cells were cultured 
for 24 h in media without antibiotics, and then growth-arrested for 16 h in Ham's F-12K 
supplemented with 0.1% BSA, supplemented with penicillin (100 U/ml), streptomycin (100 
μg/ml), before stimulation with TNFα (4 ng/ml). 
 
2.8 Statistical analysis 
Statistical analysis was performed using either the Student's unpaired t test, one-way or two-way 
ANOVA followed by Bonferroni’s post-test. P values <0.05 were sufficient to reject the null 
hypothesis for all analyses. Data are mean+SEM of n≥3 independent replicates. 
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3. Results 
3.1 PP2A activators, FTY720 and AAL(S), enhance TNFα-induced PP2A phosphatase 
activity in A549 cells 
PP2A is a ubiquitous enzyme that exerts basal phosphatase activity. In confirmation of our 
earlier study [17], we show in Figure 1 that this basal activity can be significantly increased by 
stimulation for 1 h with TNF (P<0.05). We then examined the impact of two PP2A activators: 
1) the classical PP2A activator - FTY720; 2) the novel PP2A activator and chiral analog of 
FY720 devoid of S1P agonism – AAL(S). Notably, both PP2A activators can significantly 
augment TNF-induced PP2A activity (Figures 1A & 1B: P<0.05), but are without effect when 
added to unstimulated cells. 
 
3.2 PP2A activators, FTY720 and AAL(S), significantly repress TNFα-induced IL-8 and 
IL-6 mRNA expression and protein secretion 
We then wished to examine the impact of PP2A activation with FTY720 and AAL(S) on TNF-
induced expression kinetics of two TTP targets - IL-8 (Figure 2) and IL-6 (Figure 3). As shown 
in Figure 2, TNF significantly increased IL-8 mRNA expression (Figures 2A & 2C) and protein 
secretion (Figures 2B & 2D) from A549 cells (P<0.05). Significant levels of IL-8 mRNA 
expression was first observed at 1 h and remained elevated throughout the 24 h period (P<0.05). 
Protein production ensued with significantly elevated levels of IL-8 secretion detected from 4 h 
(P<0.05). Notably, TNF-induced cytokine production could be repressed by pretreatment with 
PP2A activators. FTY720 significantly repressed TNF-induced IL-8 mRNA expression (Figure 
2A) and cytokine secretion (Figure 2B) (P<0.05). IL-8 mRNA expression (Figure 2C) and 
cytokine secretion (Figure 2D) was similarly repressed by pretreatment with AAL(S). To extend 
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these observations, we also examined the impact of PP2A activators on another pro-
inflammatory cytokine implicated in chronic respiratory disease - IL-6 - and results shown in 
Figure 3 confirm that PP2A activators significantly repress TNF-induced IL-6 mRNA 
expression (Figures 3A & 3C) and protein secretion (Figures 3B & 3D) from A549 cells 
(P<0.05). Notably, FTY720 and AAL(S) alone do not induce cytokine mRNA expression and 
cytokine secretion from A549 cells. 
 
3. 3 Specific knockdown of TTP with siRNA increases TNFα-induced IL-8 and IL-6 mRNA 
expression and protein secretion 
So far we have shown that PP2A activators - FTY720 and AAL(S) - increase PP2A activity and 
significantly inhibit TNF-induced IL-8 and IL-6 mRNA expression and cytokine secretion 
(Figures 1-3). We hypothesize that PP2A activators mediate their anti-inflammatory effect in a 
TTP-dependent manner. Towards testing this link, we first needed to show the impact of TTP on 
cytokine production under inflammatory conditions. To do this, we transiently transfected A549 
cells with siRNA against TTP and stimulated cells with TNF, compared to relevant controls 
(Figure 4). As expected, TNFα increased TTP mRNA (Figure 1A: P<0.05) and TTP protein 
expression (Figure 1B). As shown in Figure 4A, siRNA against TTP significantly repressed 
TNF-induced TTP mRNA expression (P<0.05). TNF-induced TTP protein production was 
similarly knocked down by siRNA against TTP, as demonstrated by Western blot (Figure 4B). 
Importantly, when TTP was reduced by siRNA, there was a corresponding increase in IL-8 and 
IL-6 mRNA expression (Figures 4C & 4E) and cytokine secretion (Figures 4D & 4F) from A549 
cells (P<0.05). These results demonstrate that TTP represses cytokine production in airway 
inflammatory conditions modeled in vitro. 
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3.4 PP2A activators do not enhance TTP mRNA expression; rather they modify TTP’s 
dynamic equilibrium 
We next sought to examine the effect of PP2A activators on the temporal regulation of TTP 
mRNA expression. As shown in Figure 5A, TNF significantly increased TTP mRNA 
expression with a peak at 1 h (P<0.05); however, this was unaffected by pretreatment with 
FTY720. Pretreatment with AAL(S) was similarly without effect on TNF-induced TTP mRNA 
expression (Figure 5B). We then examined the effect of PP2A activators on TTP protein levels. 
We initially established the temporal kinetics of TTP protein upregulation induced by TNF. 
TTP’s anti-inflammatory function is controlled by phosphorylation and there is a dynamic 
equilibrium between unphosphorylated/active and phosphorylated/active TTP. As shown in 
Figure 5C, and in confirmation of earlier studies in A549 [17, 19] and other cell types [5, 12], the 
rabbit antisera Sak21 detects different phospho-forms of TTP; the immunoreactive bands at 
higher molecular weight indicate phosphorylated TTP (inactive), while lower bands are 
unphosphorylated (active). TTP is an immediate-early gene [23] and can be detected at 1 h in 
both phosphorylated and unphosphorylated forms. By 2 h, phosphorylated TTP predominates 
and reduces over time (Figure 5C). In order to examine the effect of PP2A activators on these 
phospho-forms of TTP we focused in on the 1 h (Figure 5D) and 2 h time points (Figure 5E). As 
demonstrated by Western blotting and quantitated by densitometry, PP2A activators reduced the 
amount of TTP protein upregulated in response to TNF. This is seemingly counterintuitive, but 
we offer an explanation that is supported by recent in vivo studies [6, 24]. We propose that PP2A 
activators affect TTP’s dynamic equilibrium; shifting the equilibrium from phosphorylated 
(inactive) towards unphosphorylated (active) TTP. Because the phosphorylation of TTP both 
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inactivates TTP and protects it from proteasome-mediated degradation, we predicted that PP2A 
agonists that promoted TTP dephosphorylation would decrease total TTP protein levels. This 
was exactly the outcome observed in Figures 5D & 5E. To demonstrate that FTY720 and 
AAL(S) had no effect on another PP2A target, such as the phosphoprotein responsible for 
TNF-induced IL-8 and IL-6 production – p38 MAPK [17, 25-27] – we examined whether 
PP2A activators affected TNF-induced p38 MAPK phosphorylation. As shown in Figure 5F, 
PP2A activators had no effect on p38 MAPK activity. 
 
3.5 Specific knockdown of TTP with siRNA reverses repression of TNF-induced IL-8 and 
IL-6 mRNA expression and protein secretion by the PP2A activator FTY720  
Finally, we demonstrated a link between PP2A activation and TTP-mediated cytokine 
repression. We examined whether FTY720-mediated repression was TTP-dependent by 
knocking-down TTP with siRNA and observing the resultant effect on cytokine production. 
Figure 6A confirms that siRNA against TTP reduces TTP mRNA expression. In confirmation of 
earlier data, FTY720 significantly repressed TNF-induced IL-8 mRNA expression (Figure 6B) 
and protein secretion (Figure 6C) (P<0.05). IL-6 mRNA expression and protein secretion was 
also significantly repressed by FTY720 (Figures 6D & 6E: P<0.05). Notably, specific 
knockdown of TTP with siRNA reverses repression of IL-8 and IL-6 mRNA expression and 
protein secretion by FTY720 (Figures 6B-6E). These data support our hypothesis that PP2A 
activators mediate their anti-inflammatory effect in a TTP-dependent manner. 
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4. Discussion 
PP2A is a tri-molecular holoenzyme responsible for dephosphorylating (and hence activating) 
TTP, amongst many other targets. Small molecule PP2A activators have been developed and in 
this study we use two key examples – FTY720 and AAL(S) – to show that PP2A activators can 
enhance TTP’s anti-inflammatory function to inhibit cytokine production in a cellular model of 
airway inflammation in vitro.  
PP2A is best known for its role as a tumour suppressor responsible for the regulation of a range 
of cellular signalling pathways involved in proliferation, survival and migration in cancer [28]. 
Notably, PP2A expression/activity is reduced in a number of cancers [29, 30]. Thus, restoration 
of PP2A tumour-suppression activity by PP2A activators has emerged as a novel therapy for 
treating cancer. Excitingly, the knowledge gained from understanding of PP2A in cancer has 
propelled research into its role and function in respiratory disease. PP2A levels (and therefore 
activity) were reduced in mouse models of allergen- and rhinovirus-induced asthma [21] and 
could be reinstated pharmacologically with AAL(S) to repress hallmark features of airway 
disease [21, 22]. Notably, defects in PP2A cause corticosteroid insensitivity in severe asthma 
[31]. Reduced PP2A activity induces corticosteroid resistance and this can be reversed by the 
long-acting β2-agonist formoterol [32]. Cornell et al. [18] showed that blocking PP2A robustly 
increased IL-8 expression in A549 cell via post-transcriptional mRNA stabilization; although 
TTP was implicated, it was not directly examined. With these studies, we and others have 
underscored the importance of investigations into the regulation and pharmacological modulation 
of PP2A in airway inflammation. But PP2A dephosphorylates a number of kinases that drive 
inflammatory pathways [14-16]; whether TTP was involved remained an open question. 
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We address this herein. PP2A is the phosphatase responsible for TTP dephosphorylation [13]. 
Our earlier studies have shown the impact of PP2A inhibitors on TTP. Brook et al. [8] used a 
non-specific PP2A inhibitor calyculin A and demonstrated accumulation of the 
hyperphosphorylated in active form of TTP. More recently [17], we showed that when PP2A is 
reduced (either by a non-specific pharmacological inhibitor okadaic acid or more specifically 
with siRNA against PP2A-C) TTP is hyperphosphorylated and rendered inactive. Under these 
conditions, the homeostatic restraint that the ubiquitous enzyme PP2A exerts under basal 
conditions is lost and therefore cytokine secretion ensues.  In the current study we build upon 
these observations and exploit the capacity of known PP2A activators to enhance PP2A 
phosphatase activity to effectively shift the equilibrium from phosphorylated/inactive towards 
unphosphorylated/active TTP. 
A number of small molecules have been reported to activate PP2A [28]. To date, the best known 
of these is the sphingosine analog FTY720 (fingolimod; Gilenya (Novartis)). However FTY720 
has other targets. Most notably, FTY720 is also a functional antagonist of the S1P pathway. 
However, in this study we assert that FTY720’s repressive actions are primarily due to PP2A 
activation. This is demonstrated by the lack of effect of FTY720 on cytokine expression. For 
FTY720 to inhibit the S1P pathway, it must first be taken up by the cells, become 
phosphorylated intracellularly by sphingosine kinase 2 to FTY720-P. FTY720-P must then be 
released from cells to act back on S1P receptors (S1PR1, 3, 4, 5, but not S1PR2), internalizing 
the receptors and preventing them from being activated again by native ligand S1P (functional 
antagonism). For this reason, we suggest that if FTY720 was acting via S1PR-mediated 
pathways, it should induce cytokine production as a necessary part of its receptor-mediated 
interaction and consequent S1PR down-regulation. Instead we note a lack of effect of FTY720 
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alone on cytokine production in A549 cells (demonstrated in Figures 2A, 2B, 3A, 3B); thus, 
these data support the S1P-independence of the FTY720-mediated effects. 
However, despite the fact that FTY720 did not appear to exert S1PR-mediated effects in our 
cellular model of airway inflammation in vitro, there remains a compelling need to develop 
PP2A activators that are devoid of S1P agonism. We  have shown that S1P is elevated in asthma 
[33] and drives development of a pro-inflammatory phenotype, including IL-8 and IL-6 
expression in vitro [33-35]. To this end, a chiral analog of FTY720 that does not bind S1P 
receptors, called AAL(S) was developed [20], and we showed that it is just as effective as 
FTY720 at activating PP2A complexes in vitro and significantly represses airways disease in 
mouse models in vivo [21]. AAL(S) is an improvement on FTY720, being devoid of S1P 
agonism, and we now utilize these PP2A activators in A549 lung epithelial cells to show that 
although they do not activate PP2A when added alone, they increased TNF-induced PP2A 
activity to inhibit epithelial cell cytokine production in a TTP-mediated manner. Further 
understanding of the molecular mechanism of PP2A regulation in respiratory inflammation is 
required, but it could be speculated that PP2A activators may repress inflammation under 
inflamed (mimicked here with TNF), rather than non-inflamed conditions. 
Taken together our study confirms that PP2A is a druggable target in respiratory disease [21, 22] 
and establishes a link with TTP. Use of PP2A activators underscores the potential of enhancing 
TTP function with small molecules to reduce airway inflammation in respiratory disease. This 
new knowledge advances our understanding of the mechanistic basis of airway inflammation and 
suggests molecular strategies and avenues for future pharmacotherapeutic approaches based on 
exploiting the anti-inflammatory function of TTP. 
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Figure Legends 
Figure 1. PP2A activators, FTY720 and AAL(S), enhance TNFα-induced PP2A 
phosphatase activity in A549 cells. A549 cells were pretreated with (A) 2.5 µM FTY720 or (B) 
2.5 µM AAL(S) for 6 h, compared to vehicle-treated controls. Cells were treated with vehicle or 
TNFα (4 ng/ml) and then PP2A enzymatic activity (measured as pmol free phosphate) detected 
at 1 h. Statistical analysis was performed using one-way ANOVA then Bonferroni’s post-test 
(where * denotes a significant effect of TNF compared to vehicle-treated cells, and § denotes a 
significant effect of PP2A activators on TNFα-induced PP2A activity (P<0.05)). Data are 
mean+SEM values from n=3 independent experiments. 
 
Figure 2. PP2A activators, FTY720 and AAL(S), significantly repress TNFα-induced IL-8 
mRNA expression and protein secretion. A549 cells were pretreated with (A, B) 2.5 µM 
FTY720 or (C, D) 2.5 µM AAL(S) for 6 h, compared to vehicle-treated controls. Cells were 
treated with vehicle or TNFα (4 ng/ml) and then (A, C) IL-8  mRNA expression (results 
expressed as fold increase compared to vehicle-treated cells at 0 h) and (B, D) IL-8 protein 
secretion  measured  (results expressed as a percentage of TNF-induced IL-8 secretion at 24 h: 
i.e. B) 51,670.5±2,465.2 pg/ml and D) 48,825.4±2492.5 pg/ml ) at the indicated times. Statistical 
analysis was performed using two-way ANOVA then Bonferroni's post-test (where * denotes a 
significant effect of TNF compared to vehicle-treated cells, and § denotes significant repression 
of TNFα-induced cytokine production by PP2A activators (P<0.05)). Data are mean+SEM 
values from n=4-5 independent experiments. 
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Figure 3. PP2A activators, FTY720 and AAL(S), significantly repress TNFα-induced IL-6 
mRNA expression and protein secretion. A549 cells were pretreated with (A, B) 2.5 µM 
FTY720 or (C, D) 2.5 µM AAL(S) for 6 h, compared to vehicle-treated controls. Cells were 
treated with vehicle or TNFα (4 ng/ml) and then (A, C) IL-6  mRNA expression (results 
expressed as fold increase compared to vehicle-treated cells at 0 h) and (B, D) IL-6 protein 
secretion  measured  (results expressed as a percentage of TNF-induced IL-6 secretion at 24 h: 
i.e. B) 1,742.6±274.7 pg/ml and D) 1650.3±192.4 pg/ml) at the indicated times. Statistical 
analysis was performed using two-way ANOVA then Bonferroni's post-test (where * denotes a 
significant effect of TNF compared to vehicle-treated cells, and § denotes significant repression 
of TNFα-induced cytokine production by PP2A activators (P<0.05)). Data are mean+SEM 
values from n=4-5 independent experiments. 
 
Figure 4. Specific knockdown of TP with siRNA increases TNFα-induced IL-8 and IL-6 
mRNA expression and protein secretion. A549 cells were either left untransfected or 
transfected with scrambled control (scr) or siRNA against TTP (siRNA), then treated with 
vehicle or TNF (4 ng/ml) before: (A, B) knockdown of TTP mRNA and TTP protein 
expression confirmed at 1 h by (A) RT-PCR and (B) Western blotting (compared to -tubulin as 
loading control); (C, E) IL-8 and IL-6 mRNA expression measured at 1 h (results expressed as 
fold increase compared to untransfected vehicle-treated controls); and (D, F) IL-8 and IL-6 
protein secretion measured at 24 h. Statistical analysis was performed using Student's unpaired t 
test (where * denotes a significant effect of TNF compared to untransfected vehicle-treated 
controls, and § denotes a significant effect of siRNA against TTP compared to untransfected 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 25 
controls treated with TNF (P<0.05)). Data are mean+SEM values from n=3 independent 
experiments.  
 
Figure 5. PP2A activators do not enhance TTP mRNA expression; rather they modify 
TTP’s dynamic equilibrium. (A, B) A549 cells were pretreated with (A) 2.5 µM FTY720 or 
(B) 2.5 µM AAL(S) for 6 h, compared to vehicle-treated controls. Cells were treated with 
vehicle or TNFα (4 ng/ml) and then TTP mRNA expression measured (results expressed as fold 
increase compared to vehicle-treated cells at 0 h) at the indicated times. Statistical analysis was 
performed using two-way ANOVA then Bonferroni's post-test (where * denotes a significant 
effect of TNF compared to vehicle-treated cells (P<0.05)). Data are mean+SEM values from 
n=4-5 independent experiments. (C-F) A549 cells were treated with: (C) TNF (4 ng/ml) for 0, 
1, 2, 4, 8, 24 h; (D, E, F) pretreated with vehicle, 2.5 µM FTY720 or 2.5 µM AAL(S) for 6 h, 
then treated with vehicle or TNFα (4 ng/ml) for 1 h, 2 h or 0.25 h, respectively. Western blotting 
for TTP was performed (compared to -tubulin as loading control). Please note two bands of 
immunoreactivity for TTP: bands at higher molecular weight indicate stable phosphorylated TTP 
(inactive), while lower bands are unphosphorylated (active) but unstable. Results are 
representative Western blots or densitometric analysis (normalized to α-tubulin and expressed as 
% TNF-induced TTP protein upregulation at either 1 h (D) or 2 h (E)). Statistical analysis was 
performed using one-way ANOVA then Bonferroni’s post-test (where * denotes a significant 
effect of TNF, and § denotes a significant effect of PP2A activators on TNF-induced effects 
(P<0.05)). Data are mean+SEM values from n=3-4 independent experiments. (F) Results for p38 
MAPK phosphorylation (compared to total p38 MAPK as a loading control) are representative 
Western blots of n=3 independent experiments. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 26 
Figure 6. Specific knockdown of TTP with siRNA reverses repression of TNF-induced IL-
8 and IL-6 mRNA expression and protein secretion by the PP2A activator FTY720. A549 
cells were either left untransfected or transfected with scrambled control (scr) or siRNA against 
PP2A-C, then pretreated for 6 h with vehicle or with 2.5 µM of FTY720. Cells were stimulated 
with TNF (4 ng/ml) before: (A) knockdown of TTP mRNA expression confirmed or (B, D) IL-
8 and IL-6 mRNA expression measured at 1 h (results expressed as a percentage of TNF-
induced mRNA expression in untransfected controls); (C, E) IL-8 and IL-6 protein secretion 
measured at 24 h (results expressed as a percentage of TNF-induced protein secretion in 
untransfected controls). Statistical analysis was performed using Student's unpaired t test (where: 
* denotes significant effect of TTP against siRNA and § significant repression of TNFα-induced 
cytokine production by FTY720 (compared to untransfected controls);  denotes that specific 
knockdown of TTP with siRNA reverses repression of TNF-induced IL-8 and IL-6 mRNA 
expression and protein secretion by FTY720 (compared to untransfected controls) (P<0.05). 
Data are mean+SEM values from n=3 independent experiments. 
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Highlights 
 The mRNA destabilizing protein tristetraprolin (TTP) decays cytokines 
 But it is turned off in inflammation and PP2A can switch it on 
 We show that PP2A activators inhibit interleukin 8 (IL-8) and IL-6 via TTP activation 
 PP2A activators boost the anti-inflammatory function of TTP 
 PP2A activators are pharmacotherapeutic strategies to combat inflammation in 
respiratory disease 
